Table 1.

Clinical trials of BNCT in brain and central nervous system tumor

Time	Cancer Type	Trial ID	Phase	Case	Drug	Maximum Dose of Radiation	Outcomes (OS1/MST2)	Citation
Registered Clinical Trials
1999-2001	sGB3	NCT00115453	I/II	18	290-400 mg BPA4/kg	61.0 Gy(W)5	1y OS rate: 61%	[14]
2001-2009	GB6	NCT00115440	I/II	3	290 mg BPA/kg	29.0 Gy(W)	3m OS rate: 100%	[14]
2002-2003	GBM7	NCT00004015	I	N/A	100 mg BSH8/kg	N/A	N/A	[17-19]
2002-2005	GBM	NCT00039572	I/II	21	350 mg BPA/kg	/	N/A	[20]
2002-2006	GBM	NCT00974987	II	21	BSH## 200 mg BPA/kg	13.0 Gy-Eq9	MST: 15.6 months	[29]
2007-2013	Glioma	NCT01233492	I	2	350 mg BPA/kg	/	N/A	[21]
2009-2018	GB	UMIN000002385	II	45#	BPA##	13.0 Gy-Eq	N/A	[22]
2014-2016	Glioma	UMIN000013419	I/II	50#	BPA##	13.0 Gy-Eq	N/A	[23]
2019-2020	GBM	jRCTs051180218	II	4	BPA##	13.0 Gy-Eq	OS rate: 75%	[24]
2019-	MG10	jRCT2051190044	II	46#	400 mg BPA/kg	7.5 Gy-Eq	N/A	[38]
2022-	Glioma	NCT05737212	I/II	39#	500 mg BPA/kg	13.0 Gy-Eq	N/A	[30]
2022-	BM11	ChiCTR2200066473	I/II	6#	500-750 mg BPA/kg	N/A	N/A	[40]
Investigator-initiated Clinical Trials
1951-1961	GBM	N/A	I/II	28	~200 mg 10B borax/kg	10.0 Gy-Eq	N/A	[10]
1968-1996	Glioma	N/A	I/II	149	BSH##	N/A	2y OS: 12% (GB), 56% (AA12), 62% (low grade astrocytoma)	[11]
							MST: 21.3 months (GB), 60.4 months (AA), 55.6 months (low grade astrocytoma)
1994-1999	GBM	N/A	I/II	53	BPA##	N/A	MST: 12.8 months	[12]
1996-1999	GBM	N/A	I/II	20	BPA##	N/A	MST: 11.1 months	[12]
1997-2002	GBM	N/A	I/II	29	100 mg BSH/kg	N/A	MST: 10.4-13.2 months	[13]
1998-2007	GB	N/A	I/II	15	5 g BSH/body	N/A	MST: 25.7 months	[25]
					250 mg BPA/kg
1998-2008	GB	N/A	I/II	23	100 mg BSH/kg	59.7 Gy(W)	MST: 19.5 months; 1y OS: 60.6%; 2y OS: 37.9%	[26]
					250 mg BPA/kg
1999-2002	Glioma	N/A	I/II	9	100 mg BSH/kg	15.9 Gy	MST: 23.2 months (GB), 25.9 months (AA)	[27]
2000-2002	GBM	N/A	I	5	100 mg BSH/kg	14.2 Gy-Eq	N/A	[15]
2001-2005	GB	N/A	I/II	42	900 mg BPA/kg	15.5 Gy(W)	MST: 17.7 months (nGBM13), 22.2 months (rGBM14)	[16]
2002-2007	Glioma	N/A	I/II	22	100 mg BSH/kg	13.0 Gy-Eq	MST6: 10.8 months	[28]
					500-700 BPA/kg
2020-2022	MG	N/A	II	4	500 mg BPA/kg	29.4 Gy-Eq	N/A	[39]

¹OS: overall survival;

²MST: median survival time;

³sGB: supratentorial glioblastoma;

⁴BPA: boronophenylalanine;

⁵Gy(W): the absorbed dose of radiation considering biological effects;

⁶GB: glioblastoma;

⁷GBM: glioblastoma multiforme;

⁸BSH: sodium borocaptate;

⁹Gy-Eq: Gray Equivalent;

¹⁰MG: meningioma;

¹¹BM: brain malignancy;

¹²AA: anaplastic astrocytoma;

¹³nGBM: none-recurrent GBM;

¹⁴rGBM: recurrent GBM;

^#Number of patients panned to recruit in the registered information for ongoing trials or trials not yet updated after its predicted completion date.

^##The drug dosage is not reflected in the literature.